Home › Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
 

Keywords :   


Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes

2014-09-17 15:31:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. Omarigliptin significantly reduced HbA1c levels compared to placebo WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Mercks once-daily DPP-4 inhibitor JANUVIA (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Language: English Contact: MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (267) 305-1221 or +1 (310) 617-1067orInvestors:Justin Holko, +1 (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: for type data japanese

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
14.06DTS report finds US in-vehicle video and gaming growing rapidly
14.06Atlantic Tropical Weather Outlook
14.06Eastern North Pacific Tropical Weather Outlook
14.06Improved drought conditions? Whats the pollination season look like?
14.06EXCEDE for Swine rapidly reaches therapeutic plasma concentration levels
14.06Lessons learned from wean-to-harvest biosecurity program
14.06Atlantic Tropical Weather Outlook
14.06Eastern North Pacific Tropical Weather Outlook
More »